YOKOGAWA-ELECTRIC
1.12.2021 05:30:11 CET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed the Single Cellome™ System SS2000, a single-cell analysis solution that utilizes high-resolution images captured with a confocal microscope to automatically and accurately collect samples of specific cells and intracellular components. The SS2000 will be released in Japan, the US, and China in February 2022, with release in other markets such as Europe to follow at a later date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006183/en/
Development Background
As the smallest unit of all living organisms, cells can greatly differ from one another; hence, there is a growing focus on single-cell analysis involving the isolation and handling of individual cells, as opposed to studying a population. In recent years, with improved analytical technology, it has become possible to analyze not only single cells but also specific molecules within them. Understanding the characteristics and functions of cells and mechanisms for cell development is a very effective means for clarifying the causes of diseases, preventing them, and verifying the efficacy of new drugs. This is essential for drug discovery research and the development of precision medicine and regenerative medicine.
Conventional techniques for the analysis of intracellular components have typically involved the disruption and collection of heterogeneous cell populations, which does not allow for sampling at the individual cell level, so many components cannot be collected and essential information on cell location and morphology is lost. In addition, as this sampling is done manually, throughput is low, and it is quite difficult for even experienced researchers.
Utilizing Yokogawa’s core imaging technologies that enable the real-time analysis of minute phenomena in live cells, the Single Cellome System SS2000 incorporates new technologies that automatically and accurately control sampling operations in order to support the performance of cutting-edge life science research.
Features
Yokogawa confocal microscopy technology enables the rapid, minimally invasive imaging of living cells. Based on the high-sensitivity analysis of the high-resolution 3D images, the cells are automatically and precisely sampled using precise positioning technology.
1. Optimal selection of cells or regions within cells according to set criteria
The SS2000 analyzes images of a large number of cells within a target range and classifies them by using provided criteria such as cytoplasm area and nucleus size. It then identifies which cells are suitable for analysis and determines their sampling location. Utilizing criteria such as distance from the nucleus, image analysis can even identify optimal regions within individual cells.
2. Reliable sampling of target cells and components within individual cells
The SS2000 directly samples only target cells without detachment, retaining all positional and morphology information in the culture plate. Furthermore, the utilization of high-resolution 3D images and precise positioning technology enables the selective sampling of target organelles and cytoplasm.
3. Samples can be used for a broad range of analyses
The collected cells and intracellular components can be used for a broad range of analyses, including genetic analysis and mass spectrometry. The optimum and efficient collection of target samples improves analytical sensitivity. In addition, single living cells that have been sampled can be grown in secondary cell cultures.
Hiroshi Nakao, a Yokogawa Electric vice president and head of the Life Business Headquarters, comments, "The newly developed Single Cellome System SS2000 is a solution that will play a key role in future cell research. It provides the potential to understand not only the characteristics of single cells, but also the networks and communication between cells, allowing us to ascertain pathological mechanisms. In an era where more and more people are living to the age of 100, Yokogawa will accelerate the development and provision of solutions to protect lives, health, and safety."
About Yokogawa
Yokogawa provides advanced solutions in the areas of measurement, control, and information to customers across a broad range of industries, including energy, chemicals, materials, pharmaceuticals, and food. Yokogawa addresses customer issues regarding the optimization of production, assets, and the supply chain with the effective application of digital technologies, enabling the transition to autonomous operations.
Founded in Tokyo in 1915, Yokogawa continues to work toward a sustainable society through its 17,500 employees in a global network of 119 companies spanning 61 countries.
For more information, visit www.yokogawa.com
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130006183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release
Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
